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1. INTRODUCTION 
One of the key challenges of pharmaceutical industry is to find suitable methods to improve 
the processing, solubility and bioavailability of the available active substances. From this 
aspect, the rapidly developing nanotechnology captivated the attention of many medical 
scientists in recent years. Among others, organic and inorganic nanotubes got into the focus 
of their curiosity due to their promising properties presented in various scientific fields like 
physics, chemistry and electronics. However, the strict safety requirements of medical 
application shortly decreased the number of potential nanotube types for adaptation to 
medical use. Despite the limiting factors, some inorganic nanotubes such as titanate 
nanotubes (TNTs) proved to be feasible for therapeutic use. Thereafter several research 
works were engaged in the investigation of TNTs from the diagnostic to the active 
therapeutic fields. Considering that the term titanate nanotube covers TNTs with extremely 
diverse physicochemical properties (different tubular structure, length, drug carrying 
capacity, etc.), the unexplored medical aspects of TNTs is endless.  
Regarding the pharmaceutical goals, the most essential and informative research topics over 
the safety questions are the capacity of TNTs to carry nano-sized active pharmaceutical 
ingredients (APIs), including the capability of TNTs to be loaded with active substances and 
the association methods stabilizing the API-TNT composites, as well as the processability 
and manufacturing of API-TNT composites. 
 
2. AIMS 
The purpose of the present research is to define the potential pharma-industrial benefits of the 
utilization of hydrothermally synthesized TNT carriers in the manufacturing and stabilization 
of nano-sized active substances. Within the confines of this purpose, the present study aims to 
thoroughly investigate and determine the physicochemical properties of API-TNT composites 
as well as to reveal the utility of composite formation in tabletting with direct compression 
method.  
 
Abbreviations: API:active pharmaceutical ingredient, API-TNT: active pharmaceutical ingredient-
titanate nanotube composite, ATN: atenolol, ATN+TNT: physical mixture of atenolol and titanate 
nanotubes, ATNTi: atenolol- titanate nanotube composite, DiltHCl: dilthiazem hydrochloride, 
DiltHCl+TNT: physical mixture of dilthiazem hydrochloride and titanate nanotubes, DiltTi: 
dilthiazem hydrochloride-titanate nanotube composite, DicNa: diclofenac sodium, DicNa+TNT: 
physical mixture of diclofenac sodium and titanate nanotubes, DicTi: diclofenac sodium- titanate 
nanotube composite, DSC: differential scanning calorimetry, FT-IR: fourier-transform infrared, 
HCT: hydrochlorothiazide, HCT+TNT: physical mixture of hydrochlorothiazide and titanate 
nanotubes, HCTTi: hydrochlorothiazide-titanate nanotube composite, MS: mass spectroscopy, SEM: 
scanning electron microscopy, TEM: transmission electron microscopy, TGA: thermogravimetric 
analysis, TNT: titanate nanotube 
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The main endpoints of my research work are the followings: 
- to determine the suitability of the API-TNT composite formation method 
- to reveal the type(s) and strength of interactions inside the API-TNT composites 
- to define the influence of composite formation on the physicochemical properties and 
behaviour of the API 
- to estimate the effect of the composite formation on the formulation of tablets with direct 
compression and on the tablet properties  
- to propose potential industrial utilization of TNTs 
 
3. MATERIALS AND METHODS 
3.1. Materials 
A representative API of each Biopharmaceutical Classification System (BCS) classes was 
chosen for examination. Diltiazem hydrochloride (DiltHCl), diclofenac sodium (DicNa), 
atenolol (ATN) and hydrochlorothiazide (HCT) were supported by Sanofi-Aventis PLC, 
Hungary, Egis Pharmaceuticals PLC, Hungary, TEVA Pharmaceuticals PLC, Hungary and 
Gedeon Richter PLC, Hungary, respectively. 
Hydrothermally synthetized titanate nanotubes (TNTs) were produced by the University of 
Szeged, Department of Applied and Environmental Chemistry. 
1:1 ratio of diltiazem hydrochloride-TNT (DiltTi), diclofenac sodium-TNT (DicTi), atenolol-
TNT (ATNTi) and hydrochlorothiazide-TNT (HCTTi) composites were provided by the 
University of Szeged, Department of Applied and Environmental Chemistry. 
Tableting was carried out with the use of the following excipients: Avicel PH 112 (FMC 
Biopolymer Inc., USA), Tablettose 70 (Meggle Pharma GmbH, Germany), Talc (Ph.Eur., 
Molar Chemicals Ltd., Hungary), Magnesium stearate (Ph.Eur., Molar Chemicals Ltd., 
Hungary). 
3.2. Methods 
Morphological characterization: The morphology of the APIs, TNTs and API-TNT 
composites was investigated with a HITACHI S-4700 (Hitachi, Tokyo, Japan) scanning 
electron microscope. TNTs were also analysed with a FEI Tecnai G2 20 X-TWIN (FEI, 
Hillsboro, OR, USA) transmission electron microscope. The particle size of the TNTs was 
estimated by using Image J 1.47t (National Institute of Health, Bethesda, MD, USA) 
software. 
Structure analysis: Thermogravimetric analysis (TGA) and Differential scanning calorimetry 
(DSC) tests of APIs, TNTs, API-TNT composites 1:1 ratio physical mixtures of TNTs and 
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APIs were performed with a Mettler Toledo TGA/DSC1 simultaneous analyser (Mettler-
Toledo GmbH, Switzerland). The results were evaluated with STARe Thermal Analysis 
Software. Connected to the Mettler Toledo TGA/DSC1 simultaneous analyser, mass 
spectroscopy (MS) measurements were carried out by using a ThermostarTM GSD 320 
(Pfeiffer Vacuum GmbH, Asslar, Germany) quadrupole MS. A Thermo Nicolet Avatar 330 
(Thermo Fisher Scientific Ltd., Waltham, MA, USA) Fourier transform infrared (FT-IR) 
spectrometer with a Transmission E. S. P. accessory was used to record FT-IR spectra of the 
APIs, TNTs and API-TNT composites. 
Physical properties: The surface free energy of the APIs, TNTs and API-TNT composites 
was studied with a DataPhysics OCA 20 (DataPhysics Instruments GmbH, Filderstadt, 
Germany) optical contact angle tester. A software-controlled PTG-1 (PharmaTest 
Apparatebau AG, Germany) powder rheological tester was used to investigate the flowing 
properties of the APIs and API-TNT composites. Densification of the APIs and the API-TNT 
composites were tested with a STAV 2003 Stampfvolumeter (Engelsmann AG., Germany). 
The defined bulk density and tap density values were used to calculate the Hausner Ratio and 
Compressibility Index of the samples. 
Direct compression with excipients: Tablets of constant weight (300 mg) and quantity of API 
(50 mg) were compressed with a Korsch EK0 (E. Korsch Maschienenfabrik GmbH, Berlin, 
Germany) eccentric tablet press instrumented with strain gauges and a displacement 
transducer. Compression forces of 5.0, 7.5, 10.0, 12.5 and 15.0 kN were used for all 
compositions (Table 1) The powders were mixed with a Turbula mixer (Willy A. Bachofen 
Maschienenfabrik, Switzerland). 
Table 1. Composition of API and API-TNT tablets 
Component API tablets (300 mg) API-TNT tablets (300 mg) 
API (DiltHCl/DicNa/ATN/HCT) 16.7 % - 
API-TNT composite 
(DiltTi/DicTi/ATNTi/HCTTi) 
- 33.3 % 
Avicel PH 112 50.0 % 39.5 % 
Tablettose 70 29.3 % 23.2 % 
Talc 3.0 % 3.0 % 
Magnesium-stearate 1.0 % 1.0 % 
 
Direct compression without excipients: TNTs, APIs and API–TNT composites were 
compressed with a Lloyd 6000R uniaxial press (Ametek SAS Lloyd Inst, Elancourt, 
France), instrumented with a force gauge and a linear variable differential transformer 
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extensometer. The compacts were prepared using 50, 100, 150, 200 and 250 MPa 
pressures for each material. Force and displacement data were recorded by a computer 
(R-Control software, Version 2.0, Lloys Inst LTD, Fareham, UK) connected to the 
equipment. The retrieved data set was evaluated with Origin 7.5 software (OriginLab 
Corporation, Northampton, MA, USA) in order to determine the energy utilisation of the 
raw materials during the compression cycle. The energy analysis was expanded with the 
determination of Ri (R1, R2 and R3) values which serve to describe pressure related 
transformation of energies: mechanical energy (MCW) into theoretical energy (ThCW) 
(R1), ThCW into total energy (TCW) (R2) and TCW into net energy (NCW) (R3). 
Post-formulation methods: The compaction properties of the powder mixtures (Table 1.) 
were estimated with Kawakita and Walker out-of-the die models. Geometry of the tablets 
produced with excipients was measured with Kraemer UTS-50 tablet tester (Charles Ischi 
AG, Switzerland) right after the production and one week later. Weight, height and diameter 
of tablets produced without excipients were measured 24 hours after production with an 
analytical scale, a calliper and a Lloyd 6000R uniaxial press (Ametek SAS Lloyd Inst, 
Elancourt, France), respectively. Geometrical parmeters served to calculate the compaction 
ratio. The breaking force of the tablets fabricated with excipients were studied by a Heberlein 
2E/205 tablet hardness tester (HeberleinAG, Switzerland), while that of the tablets 
compressed without excipients was tested with a Lloyd 6000R uniaxial press (Ametek SAS 
Lloyd Inst, Elancourt, France). The breaking force results were also used to calculate the 
stensile strengths. The texture of the breaking surface of the tablets fabricated with 
excipients was investigated with a Hitachi S4700 (Hitachi Ltd., Japan) scanning electron 
microscope. Disintegration was determined for tablets fabricated with excipients with an 
Erweka ZT71 (Erweka GmbH, Germany) disintegration tester apparatus. Drug dissolution 
from tablets compressed with excipients was examined in pH 1.2 and pH 6.8 dissolution 
media by using an Erweka DT700 (Erweka GmbH, Heusenstamm, Germany) dissolution 
tester, applying paddle method. Results were evaluated a ThermoScientific GENESYS 10S 
UV-VIS spectrophotometer (Thermo Fisher Scientific Ltd., Waltham, MA, USA). 
 
4. RESULTS 
4.1. Material properties: APIs, TNTs, API-TNT composites 
4.1.1. Morphology 
Based on the TEM pictures, the average diameter of the TNTs was determined to be 7.01 nm 
(SD ±1.08 nm) while the length, which is a matter of the synthesis parameters, was found to 
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be 164.25 nm (SD ± 50.38 nm). The SEM pictures allowed concluding that TNTs are not 
present individually but in form of aggregates (Fig. 1). 
The SEM images of the composites (Fig. 2) revealed that the efficacy of drug incorporation 
was not equal for all 4 APIs. While the composite formation of DiltHCl and DicNa seemed to 
be ideal and resulted in homogenous composite products, that of ATN and HCT was only 
partially effective and left several individual API crystals in the final products, as shown by 
yellow arrows on Fig. 2. Based on the pictures, the ATNTi product seems like the physical 
mixture of the source materials, while in case of the HCTTi product, a kind of reverse 
mechanism of the composite formation could be recognized inducing that approx. 60% of the 
API crystals are covered with TNTs. 
 
Figure 1. TEM micrograph (a) and SEM micrograph (b) of titanate naotubes 
 
Figure 2. SEM images of the DiltTi (a), DicTi (b), ATNTi (c) and HCTTi (d) 
4.1.2. Surface free energy 
TNTs have high surface free energy confirming their expected hydrophilic nature. This 
character of the TNTs is reflected in the γTOT values of the ATNTi and HCTTi composites 
which showed increment in this value in comparison with the pure ATN and HCT, 
respectively. The increment in γTOT may be attributable to the incomplete composite 
formation which resulted in the surface coverage of the API crystals with TNTs. The extent 
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of increment is considered as an indicative of the ratio of the surface coverage. As regards the 
DiltTi and DicTi composites, a decrease of γTOT value and polarity could be noticed in 
comparison with both the TNTs and the pure APIs (DiltHCl and DicNa, respectively). This 
finding confirms the successful incorporation of DiltHCl and DicNa and that the APIs are not 
only located in the internal part of the nanotubes but are also bonded to the surface. The 
decrease of γTOT and polarity indicates hydrophilic intermolecular interactions on the surface 
of the TNTs inducing the enrichment of the hydrophobic molecular parts on the particle 
surface. The higher decrease in surface free energy suggests a greater bonding ratio on the 
surface of the TNTs. 
4.1.3. Thermal properties 
The resume of the thermoanalytical measurements shows a clear tendency. Fig. 3. serves as 
an example to support the statements. TNTs shift the fusion of an API to lower temperatures 
which may be due to the decreased particle size and/or to the interactions of the API and 
TNTs. The decreased relative enthalpy of the peaks indicates that the composite formation 
puts the system into an energy minimum. 
 
Figure 3. DSC, TG and DTG curves of DiltHCl, DiltTi, DiltHCl+TNT and TNT 
The long-lasting decomposition is probably due to the TNT-API interactions on the 
interfacial surface, which may be observed both for physical mixtures and composites, but 
increased rate of extension was noticed in latter case. This may be due to the certainly 
stronger interactions inside the composites, or can be explained by the location which results 
immediate decomposition of the surface-attached API, while the drug locked inside the 
nanotubes decomposes with a time lag.  
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Overall, it can be established that DicNa and HCT are perfectly suitable to form stable API-
TNT composites, while DiltHCl and ATN are less capable to form strong interactions with 
the TNTs. 
4.1.4. FT-IR 
The results of the FT-IR examination confirmed the thermoanalytical findings and also 
provided new essential information about the structure of the API-TNT composites. The 
assessment of the results pointed out that the strength of the association inside the composites 
is based on the hydrogen donor strength of the incorporated API. The hydrogen acceptor 
groups of the API play only a minor role in the association which can be explained by the 
high quantity of OH groups (having poor hydrogen donating capacity) on the titanate surface 
(Fig. 4). 
 
Figure 4. Association mechanism of APIs (DiltHCl, DicNa, ATN, HCT) with TNTs 
4.1.5. Powder rheology 
Based on the powder rheological properties (Table 10) it can be established that TNTs have 
good flowability and this affects the flow properties of the incorporated APIs in a positive 
way; a great improvement of flowability is shown by DiltTi and DicTi compared to DiltHCl 
and DicNa, but the flowability improvement of ATNTi and HCTTi was less defined since 
these composites contain individual API crystals. By evaluating the results as per the United 
States Pharmacopeia (USP) scale, it is clear that the flowability of the composites varies 
between those of the component materials. This can be explained by the fact that the APIs are 
located not only in the internal parts of the TNTs but on their surface as well. The rate of 
improvement may depend on the ratio of the surface coverage. 
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4.1.6. Compressibility and compactibility 
The post-compressional properties of tablets are summarized in Fig. 5, providing a complex 
image of the tablettability of the investigated materials. 
Tablets prepared from pure APIs may be characterized by high (approx. 75–90 %) 
compaction ratio at low pressure which shows slight increase with the increment of 
compression pressure. Despite of the high compressibility, API tablets display very low 
tensile strengths indicating their poor compactibility. In contrast, TNTs show poor (approx. 
55 %) compaction ratio at low compression force, but still result in tablets of high tensile 
strength in the whole compression force range and can be considered adequate for tabletting. 
The results of the composite tablets need to be assessed one by one due to the unique 
characteristics. However, a clear tendency of improved tablettability can be established based 
on Fig. 5. It can be stated in general, that the composite tablets have higher tensile strength 
induced at lower compaction ratios compared to the API tablets, which indicates that hard 
tablets can be produced with relatively high porosity, providing considerable benefits in drug 
release.  
 
Figure 5. Evaluation of the tensile strength vs. the compaction ratio of the investigated 
materials compressed with 50, 100, 150, 200 and 250 MPa compression pressure 
 
Based on the results, DiltTi and DicTi tablets (where the APIs are well incorporated into the 
TNTs) have morefold higher tensile strengths compared to the DiltHCl and DicNa tablets at 
same compaction ratios. Furthermore, an immense improvement in tablettability could be 
recognized for DicNa/DicTi as the strong lamination of the DicNa tablets completely 
disappeared due to the composite formation. In case of the incompletely incorporated APIs 
(ATN and HCT), the properties of the composite tablets reflect a special mixture of the 
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characteristics of the source materials. As regards the ATNTi, this resulted in relatively bad 
tablet properties which again prove the physical-mixture-like character of the ATNTi 
product. As concerns the HCTTi composite, the deficient incorporation of HCT induced more 
beneficial properties to the composite product than expected. The HCTTi tablets display not 
only far better tablet properties than all the other composites, but show even more favourable 
ones that the pure TNTs. This interesting phenomenon is probably due to the positive 
consonance of the reverse interaction between the HCT and the TNTs, and the good 
compactibility of both source materials. 
4.2. Powder mixtures: APIs, API-TNT composites with excipients 
4.2.1. Compressibility and compactibility 
The constant values calculated by applying Kawakita-Lüdde and Walker models are 
summarized in Table 2. 
Table 2. Parameters calculated from Kawakita and Walker plots 
Tablet a 1/b L W 
DiltHCl 0.68 8.03 7.9 11.59 
DiltTi 0.62 18.63 5.93 16.49 
DicNa 0.67 6.38 9.85 8.72 
DicTi 0.68 13.53 6.64 14.73 
ATN 0.64 5.94 13.56 4.04 
ATNTi 0.65 17.61 8.47 9.43 
HCT 0.61 14.32 12.89 7.01 
HCTTi 0.68 6.04 17.76 2.49 
 
The constant a values (Table 2), which demonstrate the rearrangement of the particles, are 
very similar for all the samples. Despite the fact that the results obtained for the raw materials 
presumed lower constant a values for the API-TNT tablet compositions, no considerable 
differences occurred neither within the API tablet compositions nor between the API and the 
related API-TNT tablet compositions. This allows concluding that the excipients were 
appropriately selected and could compensate the poor flow properties of APIs during 
packaging. However, it is notable that API-TNT powder mixtures contain proportionally less 
excipient than those of the APIs which means that TNTs could replace the function of the 
excipients. 
The calculated 1/b values correlate with the cohesiveness (Table 2). The high 1/b values of 
the API-TNT tablet compositions are in accordance with the smaller compaction ratios of the 
API-TNT composites (Fig. 5). The low 1/b values of the API tablet compositions is due to the 
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fast collapse of the powder bed in the die resulting limited compressibility as it was observed 
for the pure API powders (Fig. 5.). It is clear from the results that the behaviour of the HCT 
and HCTTi tablet compositions is exceptional since the HCT tablet composition has a quite 
high 1/b value, while the HCTTi tablet composition displays an unexpectedly low 1/b value. 
This phenomenon is probably due to the inverse composite formation mechanism which 
results in higher surface free energy and adhesivity of HCTTi compared to the pure HCT, 
which is resulted in decreased compactibility. 
The values of coefficient L (Table 12) were lower for the API-TNT tablet compositions, 
indicating higher volume reduction of the composite containing compositions at a certain 
pressure in the deformation phase compared to the API tablet compositions. The opposite 
behaviour of the HCT/HCTTi tablet compositions appeared here as well due to the previously 
mentioned structural properties of the composite. 
The coefficient W value correlates with the irreversible compressibility of the powders (Table 
2). Accordingly, the higher W values of the API-TNT tablet compositions reflect to their 
plastic deformation while the lower values displayed by the API tablet compositions refer to 
their high elastic recovery resulting in an exceeded densification maximum. These findings 
are in accordance with the results obtained for the deformation mechanism of the raw 
materials. Here again, the behaviour of the HCT/HCTTi tablet powder mixtures occurred to 
be just the opposite of that of the other API/API-TNT tablet compositions for the already 
mentioned reason. 
In general, it can be concluded that the results of the powder mixtures correlate well with the 
observations of the energetic analysis of the raw materials. The only exception is the case of 
HCT/HCTTi, where the raw materials indicate the positive effect of the composite formation, 
while this effect seems unfavourable in the powder mixtures. 
Overall, it can be established that the incorporation of drugs into TNTs has a positive effect 
on the tablettability and therefore TNTs can be considered as a multifunctional excipient in 
tablet production. However, it is important to note that an unsuccessful composite formation 
can even lead to a worse tablettibility profile than expected from the pure API itself. 
4.2.2. Tablet properties 
As expected, the tablets showed increased apparent density with the increase of the 
compression force. The only exception was noticed for the ATN tablets during the 0 h 
measurements, where the density decreased with the increase of the compression force. This 
indicates the strong elasticity of the ATN, which corresponds with the low coefficient W 
value of the ATN tablet composition (Table 2). The previously established positive effect of 
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TNTs on the deformation mechanism is confirmed by the fact that no such phenomenon was 
identified for the ATNTi tablets. API-TNT tablets have higher apparent densities at all 
investigated compression pressures than the corresponding API containing tablets indicating 
that the presence of TNTs generally increases the apparent density of the produced tablets. 
When comparing the apparent density changes in time, it turned out that no remarkable 
density changes occurred for those API-TNT tablets where the composite formation was 
complete (DiltTi and DicTi tablets) while tablets containing incomplete composites (ATNTi 
and HCTTi tablets) showed increased apparent density after one-week storage at all 
compression forces. 
As concerns the breaking strength of the tablets, it increases with the compression pressure 
for every tablet compositions, but the increment is greater for the API-TNT tablets than for 
the API tablets. Furthermore, the breaking strengths of the API-TNT tablets are much 
superior to those of the API tablets at all compression forces. These results are in agreement 
with the compaction properties of the powder mixtures (Table 2) and the raw materials as 
well (Fig. 5). 
Supporting the expectations, the disintegration time appeared to be proportional with the 
compression pressure in all cases and the disintegration time of the API-TNT tablets is longer 
than that of the corresponding API tablets which correlates with their greater hardness. 
The results of the dissolution tests in pH 6.8 phosphate buffer are displayed in Fig. 6. 
Regarding to the expectations no considerable change was observed in the dissolution 
profiles of the well soluble DiltHCl/DiltTi or ATN/ATNTi tablets, except of the decreased 
dissolution speed with the increasing compression pressure or resulted by the bigger density 
of the API-TNT tablets. The dissolution profiles of the HCT/HCTTi tablets were also highly 
similar, which may be due to the incomplete incorporation and non-considerable particle size 
decrease of HCT. In contrast, considerable changes in drug release profile were noted for the 
DicNa/DicTi tablets, due to the strong drug-carrier interactions. The dissolution from DicNa 
tablets follows a first order dissolution profile as per Noyes-Whitney equation, while DicTi 
tablets shows prolonged drug release kinetics according to Korsmeyer-Peppas equation. In 
this case the TNTs act as a standalone matrix system, which may be utilized as modified-
release drug delivery system. Furthermore, in contrast with the other investigated API/API-
TNT tablets, an improved dissolution rate was observed from DicTi tablets compared to 
DicNa tablets in artificial gastric juice (Fig. 7). 
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Figure 6. Dissolution study of API and API-TNT tablets in phosphate buffer 
 
Since DicNa is poorly soluble under gastric conditions, this phenomenon may be due to the 
particle size decrease of DicNa which doubled the rate and the amount of the dissolved API. 
This observation is essential since it proves the solubility increasing capacity of TNTs. 
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Figure 7. Dissolution from DicNa and DicTi 5kN tablets in artificial gastric juice 
It can be generally stated that the first phase of dissolution is driven by the disintegration, 
while the slower drug dissolution in the further phases is attributed to the interactions inside 
the composites which retain the incorporated APIs from the quick release to different extent. 
Overall, the dissolution studies allowed concluding that the presence of TNTs increases the 
tablet strength and results prolonged drug release without reference to the success of the 
composite formation process. However, in case of successful drug incorporation and 
adequate strength of interactions inside the composite, TNTs can modify the kinetics of the 
drug dissolution., or in the case of an ideal composite formation process, TNTs are able to 
improve the solubility of the incorporated drug by decreasing its particle size. 
 
5. CONCLUSION 
The main consequences of the research may be summarized as follows. 
The measurements revealed that only two (DiltHCl and DicNa) out of the four investigated 
APIs were successfully incorporated into the TNTs. It indicates that the applied composite 
formation method is only conditionally suitable since its efficacy highly depends on the 
physicochemical properties of the drug to be incorporated. Therefore, further optimization of 
the method may be required before use. 
We have determined that API-TNT interactions are principally based on hydrogen bonds and 
the strength of the association depends on the hydrogen donor strength of the incorporated 
API. The hydrogen acceptor groups of the API play only secondary role in the association 
due to the high quantity, but poor hydrogen donating capacity of OH groups on the surface of 
titanate nanotubes. Accordingly, the strongest association was seen for DicTi and HCTTi 
among the investigated composites. 
The API-TNT association and the particle size reduction resulted decreased fusion 
temperature and enthalpy, and modified and elongated decomposition of the APIs. The 
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change in the thermal behaviour was affected by the strength of interactions, therefore the 
most important differences were observed for the DicNa/DicTi and HCT/HCTTi samples.  
The image analysis and surface energy measurements revealed that the API may be located 
both in the inner parts and on the surface of the TNTs. The resulted decrease of the surface 
free energy may lead to improved flow and packaging characteristics. 
The good tabletting properties of the TNTs highly improved the tablettability of the 
incorporated APIs due to improved flowability, packaging, extended range of compressibility 
and better compactibility. However, these effects showed considerable dependence on the 
efficacy of the incorporation and therefore the best results were recorded for DiltHCl and 
DicNa. As regards the post-compressional tablet properties, the composite formation 
extremely improved the tablet strength, increased the density and therefore slowed down the 
disintegration and prolongated the drug dissolution. The positive effect of TNTs on the tablet 
properties was far less influenced by the success of the incorporation than observed for other 
parameters. 
Nevertheless, TNTs may affect the drug release from the composite product by acting as a 
matrix and retaining the release of the API over certain strength of interactions, as was 
observed in the case of DicNa. However, the decreased particle size may lead to better 
solubility of poorly soluble drugs, especially if the release is not disintegration-driven, as was 
observed in the case of 5kN DicTi tablets in artificial gastric juice. 
Finally, this research proved that drug loaded TNTs can successfully and easily be formulated 
into tablets with direct compression method, since they are capable to improve every step of 
the tabletting cycle and lead to favourable tablet properties even when used in small quantity 
and when compared to other excipients. Accordingly, TNTs have the potential to replace and 
over fulfil one or more excipients in a tablet composition and therefore can improve and 
simplify the production. Furthermore, if the API is correctly incorporated in the TNTs, these 
carriers can improve the drug solubility which may be promising for pharma-industry since 
TNTs can become alternatives of available nanocarriers with fundamental manufacturing 
problems such as dendrimers, liposomes, etc. In addition, by carrying nanosized drugs, TNTs 
may overcome the autoaggregation induced formulation difficulties of nanocrystalline APIs. 
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